BiotechTube
Home/Pipeline/Undisclosed

Undisclosed

Not Specified

Pre-clinicalActive

Key Facts

Indication
Not Specified
Phase
Pre-clinical
Status
Active
Company
Authera

About Authera

Authera leverages deep scientific expertise in FcRn biology to de-risk and accelerate the development of next-generation biologics. Founded in 2022 by a team of renowned academics and entrepreneurs, the company has secured non-dilutive grant funding to advance its lead candidate, AuT-1, for severe eye diseases. Authera's strategy combines advancing its own pipeline with establishing science-driven partnerships to explore the broad therapeutic potential of its FcRn-focused platform.

View full company profile

Therapeutic Areas

OphthalmologyImmunology

Other Not Specified Drugs

DrugCompanyPhase
Inflammation ProgramsArcus BiosciencesNot Specified
Bone Marrow Conditioning ProgramTelix PharmaceuticalsPipeline
AGMB-447Agomab TherapeuticsNot Disclosed
AGMB-101Agomab TherapeuticsNot Disclosed
TRIFERTY-ATM®Laboratorio Reig JofreApproved/Commercial
AGEN1571 (anti-ILT2)AgenusNot specified
AGEN1777AgenusNot specified
AGEN1721AgenusNot specified
INCAGN1876 (GITR Agonist)AgenusNot specified
INCAGN1949 (OX40 Agonist)AgenusNot specified
AGEN1327 (anti-TIGIT)AgenusNot specified
AGEN2373 (CD137 Agonist)AgenusNot specified